RxDoctor Payments Data

Amy Zeller, PA

Physician Assistant · Waterloo, ILNPI 1326539859

Payments from drug & device makers

$6,549in general payments, 2019–2025

Across 404 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$772
  • Novo Nordisk$711
  • AbbVie$674
  • Pfizer$390
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$239
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$6,549100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,549 in reported general payments places this provider in the 95th percentile of 3,912 physician assistant providers in Illinois.

See all physician assistant providers in Illinois

Medicare billing

Part B allowed, 2024
$15,286
Medicare patients
86
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban15$13,752
MounjaroTirzepatide14$13,079
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,223
Methenamine Hippurate13$1,196
Albuterol Sulfate HfaAlbuterol Sulfate30$762
Montelukast Sodium28$639
Gabapentin26$485
Carvedilol34$424
Atorvastatin Calcium48$349
Fluticasone Propionate22$338
Omeprazole35$289
Potassium Chloride19$278
Pantoprazole Sodium25$273
Pregabalin11$264
Ezetimibe11$259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$230$13,75215 claims
Lilly USA, LLCMounjaro$772$13,07914 claims
AstraZenecaBreztri Aerosphere$1,560$10,22316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,912 physician assistant providers in Illinois.

Other physician assistant in Waterloo

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →